These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26702022)

  • 21. High-Throughput Screening for Drug Combinations.
    Shinn P; Chen L; Ferrer M; Itkin Z; Klumpp-Thomas C; McKnight C; Michael S; Mierzwa T; Thomas C; Wilson K; Guha R
    Methods Mol Biol; 2019; 1939():11-35. PubMed ID: 30848454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Automation of a phospho-STAT5 staining procedure for flow cytometry for application in drug discovery.
    Malergue F; van Agthoven A; Scifo C; Egan D; Strous GJ
    J Biomol Screen; 2015 Mar; 20(3):416-21. PubMed ID: 25325258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advantages and limitations of total laboratory automation: a personal overview.
    Lippi G; Da Rin G
    Clin Chem Lab Med; 2019 May; 57(6):802-811. PubMed ID: 30710480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compound Transfer by Acoustic Droplet Ejection Promotes Quality and Efficiency in Ultra-High-Throughput Screening Campaigns.
    Dawes TD; Turincio R; Jones SW; Rodriguez RA; Gadiagellan D; Thana P; Clark KR; Gustafson AE; Orren L; Liimatta M; Gross DP; Maurer T; Beresini MH
    J Lab Autom; 2016 Feb; 21(1):64-75. PubMed ID: 26077161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-density self-contained microfluidic KOALA kits for use by everyone.
    Guckenberger DJ; Berthier E; Beebe DJ
    J Lab Autom; 2015 Apr; 20(2):146-53. PubMed ID: 25424385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases.
    Paveley RA; Mansour NR; Hallyburton I; Bleicher LS; Benn AE; Mikic I; Guidi A; Gilbert IH; Hopkins AL; Bickle QD
    PLoS Negl Trop Dis; 2012; 6(7):e1762. PubMed ID: 22860151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reagent and labor cost optimization through automation of fluorescence in situ hybridization (FISH) with the VP 2000: an Italian case study.
    Zanatta L; Valori L; Cappelletto E; Pozzebon ME; Pavan E; Dei Tos AP; Merkle D
    J Lab Autom; 2015 Feb; 20(1):25-31. PubMed ID: 25395292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
    Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
    Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Label-free screening assays: a strategy for finding better drug candidates.
    Lunn CA
    Future Med Chem; 2010 Nov; 2(11):1703-16. PubMed ID: 21428840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JALA special issue: microengineered cell- and tissue-based assays for drug screening and toxicology applications.
    Huh DD; Kim DH
    J Lab Autom; 2015 Apr; 20(2):79-81. PubMed ID: 25795434
    [No Abstract]   [Full Text] [Related]  

  • 31. Using the BioAssay Ontology for analyzing high-throughput screening data.
    Zander Balderud L; Murray D; Larsson N; Vempati U; Schürer SC; Bjäreland M; Engkvist O
    J Biomol Screen; 2015 Mar; 20(3):402-15. PubMed ID: 25512330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Automation of cell-based drug absorption assays in 96-well format using permeable support systems.
    Larson B; Banks P; Sherman H; Rothenberg M
    J Lab Autom; 2012 Jun; 17(3):222-32. PubMed ID: 22357561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a Platform to Enable Fully Automated Cross-Titration Experiments.
    Cassaday J; Finley M; Squadroni B; Jezequel-Sur S; Rauch A; Gajera B; Uebele V; Hermes J; Zuck P
    SLAS Technol; 2017 Apr; 22(2):195-205. PubMed ID: 27864339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-throughput sample processing and sample management; the functional evolution of classical cytogenetic assay towards automation.
    Ramakumar A; Subramanian U; Prasanna PG
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():132-41. PubMed ID: 26520383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Designs and concept reliance of a fully automated high-content screening platform.
    Radu C; Adrar HS; Alamir A; Hatherley I; Trinh T; Djaballah H
    J Lab Autom; 2012 Oct; 17(5):359-69. PubMed ID: 22797489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Design of an Incremental and Open Laboratory Automation System].
    Xie C; Chen Y; Wang Z
    Zhongguo Yi Liao Qi Xie Za Zhi; 2015 Jul; 39(4):268-71. PubMed ID: 26665947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compound screening: Fresh hunting ground.
    McGilvray A
    Nature; 2016 May; 533(7602):S65-7. PubMed ID: 27167395
    [No Abstract]   [Full Text] [Related]  

  • 38. A computational method for planning complex compound distributions under container, liquid handler, and assay constraints.
    Russo MF; Wild D; Hoffman S; Paulson J; Neil W; Nirschl DS
    J Lab Autom; 2013 Oct; 18(5):391-403. PubMed ID: 23603752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.
    Houston JG; Banks MN; Binnie A; Brenner S; O'Connell J; Petrillo EW
    Drug Discov Today; 2008 Jan; 13(1-2):44-51. PubMed ID: 18190863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adapting a Low-Cost Selective Compliant Articulated Robotic Arm for Spillage Avoidance.
    McMorran D; Chung DC; Li J; Muradoglu M; Liew OW; Ng TW
    J Lab Autom; 2016 Dec; 21(6):799-805. PubMed ID: 26882923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.